Dupixent (dupilumab) made more than €5 billion last year from its current uses in atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps, and EoE is one of a clutch ...

SNY Sanofi Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis ...

Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, the tube that carries food and liquids from the mouth to the stomach. EoE causes symptoms like difficulty ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Eosinophilic esophagitis is now an established cause of dysphagia. Gastroenterologists should have a high clinical suspicion for this condition if the characteristic clinical and endoscopic ...

The major differential diagnoses of eosinophilic esophagitis are GERD and peptic strictures. Table 1 describes the differences between GERD and eosinophilic esophagitis. The clinical history ...

“Eosinophilic esophagitis is becoming increasingly common all over the world, yet remains fundamentally neglected when it comes to effective, tolerable treatments,” said Andrea Choe, M.D., Ph ...

Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line for ...

SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.